WEC
GSK icon

Winslow Evans & Crocker’s GSK GSK Stock Holding History

Winslow Evans & Crocker’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$531K Buy
11,540
+6,048
+110% +$278K 0.1% 194
2020
Q3 		$258K Sell
5,492
-279
-5% -$14K 0.06% 243
2020
Q2 		$294K Sell
5,771
-5
-0.1% -$257 0.08% 231
2020
Q1 		$274K Buy
5,776
+259
+5% +$13.8K 0.09% 207
2019
Q4 		$324K Hold
5,517
– – 0.08% 229
2019
Q3 		$296K Sell
5,517
-3
-0.1% -$154 0.08% 241
2019
Q2 		$278K Sell
5,520
-242
-4% -$12.1K 0.08% 250
2019
Q1 		$302K Buy
5,762
+474
+9% +$23.7K 0.09% 230
2018
Q4 		$254K Hold
5,288
– – 0.09% 230
2018
Q3 		$266K Hold
5,288
– – 0.08% 232
2018
Q2 		$268K Sell
5,288
-280
-5% -$14.1K 0.08% 219
2018
Q1 		$272K Hold
5,568
– – 0.09% 216
2017
Q4 		$247K Sell
5,568
-302
-5% -$14K 0.08% 229
2017
Q3 		$298K Sell
5,870
-332
-5% -$16.8K 0.1% 201
2017
Q2 		$334K Sell
6,202
-1
-0% -$53 0.09% 234
2017
Q1 		$327K Buy
6,203
+280
+5% +$14.2K 0.1% 210
2016
Q4 		$285K Sell
5,923
-6,381
-52% -$315K 0.09% 238
2016
Q3 		$663K Buy
12,304
+6,405
+109% +$351K 0.19% 113
2016
Q2 		$320K Buy
5,899
+1
+0% +$53 0.1% 204
2016
Q1 		$299K Buy
5,898
+79
+1% +$3.94K 0.09% 205
2015
Q4 		$293K Hold
5,819
– – 0.08% 232
2015
Q3 		$280K Hold
5,819
– – 0.09% 225
2015
Q2 		$303K Sell
5,819
-627
-10% -$35.3K 0.09% 235
2015
Q1 		$372K Hold
6,446
– – 0.11% 206
2014
Q4 		$344K Hold
6,446
– – 0.1% 208
2014
Q3 		$370K Buy
6,446
+400
+7% +$24.5K 0.11% 207
2014
Q2 		$404K Sell
6,046
-127
-2% -$8.6K 0.13% 175
2014
Q1 		$412K Sell
6,173
-320
-5% -$21.6K 0.14% 163
2013
Q4 		$433K Buy
+6,493
New +$421K 0.15% 167

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Winslow Evans & Crocker's GSK Position: Q4 2020 in Review

Winslow Evans & Crocker increased its GSK (GSK) stake by 110% in Q4 2020, buying an estimated $278K and bringing the position to 11,540 shares worth $531K. The position accounts for 0.1% of the portfolio, ranked #194.

Winslow Evans & Crocker first reported a position in GSK in Q4 2013 and has held it in 29 quarters since. The position peaked at $663K in Q3 2016. 818 funds tracked by Wall St. Rank hold GSK as of Q4 2020.

  • Winslow Evans & Crocker held 11,540 shares of GSK worth $531K as of Q4 2020.
  • Winslow Evans & Crocker bought 6,048 GSK shares in Q4 2020, an estimated $278K.
  • GSK made up 0.1% of Winslow Evans & Crocker's portfolio in Q4 2020, its #194 holding.
  • Winslow Evans & Crocker first reported a position in GSK in Q4 2013 and has held it in 29 quarters since.
  • Winslow Evans & Crocker's GSK position peaked at $663K in Q3 2016.
  • 818 funds tracked by Wall St. Rank held GSK as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.